(#41) Long-acting Injectable Treatments for Schizophrenia: Differences in Attitudes and Preferences Among Healthcare Professionals and Patients From the SOLARIS Trial Experiences Study

Abstract: TV-44749 is an innovative, once-monthly, subcutaneous (SC) long-acting injectable (LAI) olanzapine. TV-44749 is designed to provide sustained efficacy without oral supplementation and complex initiation regimens, and to eliminate the risk of post-injection delirium/sedation syndrome (PDSS) and the Risk Evaluation and Mitigation Strategy (REMS) requirements associated with intramuscular (IM) LAI olanzapine. This survey study complemented the SOLARIS trial (NCT05693935), a Phase 3 trial of TV-44749 in adults with schizophrenia. Surveys assessed the attitudes and experiences of patients and healthcare professionals (HCPs) regarding LAI treatment attributes. Overall, 70 patients and 35 HCPs (11 physicians; 24 nurses) were surveyed. While HCPs did not report a particular injection-type preference, 78.6% of patients preferred SC over IM injection, with SC preference attributed to a shorter/thinner needle (67.3%). Most HCPs (77.1%) reported that LAIs are not a daily reminder of illness as a benefit over oral medication; only 35.7% of patients agreed. The majority of HCPs (74.3%) reported that LAIs result in less conflict with caregivers; only 22.9% of patients reported the same. Most physicians (72.7%) reported that PDSS risk interfered with LAI prescription or administration; only 20.8% of nurses agreed. Nearly half of patients (45.7%) indicated that a post-injection monitoring period would have a social, financial, time, or emotional impact, and most (90.0%) indicated an LAI without this monitoring period would be helpful. These descriptive results highlight disconnects in preferences and attitudes among patients and HCPs regarding LAI attributes and delivery of care, identifying opportunities where education could improve understanding and widespread adoption of LAIs.Short Description: This descriptive study assessed the attitudes and experiences of patients and healthcare professionals (HCPs) with ?2 experiences with TV-44749 in the SOLARIS trial. While participants reported satisfaction with TV-44749 overall, these results demonstrate differences in the preference and attitudes of patients and HCPs regarding perceived benefits of LAI attributes and delivery of care. Opportunities where education may address existing barriers to LAI understanding and adoption were identified.Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC